S J Schuster
Overview
Explore the profile of S J Schuster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghilardi G, Chong E, Svoboda J, Wohlfarth P, Nasta S, Williamson S, et al.
Ann Oncol
. 2022 Jun;
33(9):916-928.
PMID: 35690221
Background: Anti-CD19 chimeric antigen receptor T-cell immunotherapy (CAR-T) is now a standard treatment of relapsed or refractory B-cell non-Hodgkin lymphomas; however, a significant portion of patients do not respond to...
2.
Mato A, Hill B, Lamanna N, Barr P, Ujjani C, Brander D, et al.
Ann Oncol
. 2017 Apr;
28(5):1050-1056.
PMID: 28453705
Background: Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence. Patients And Methods: We conducted...
3.
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al.
Ann Oncol
. 2017 Apr;
28(7):1436-1447.
PMID: 28379322
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased....
4.
Ruan J, Shah B, MARTIN P, Schuster S
Ann Oncol
. 2016 Apr;
27(7):1226-34.
PMID: 27052651
Lenalidomide is an oral immunomodulatory drug with significant activity in indolent B-cell and mantle cell lymphomas. Lenalidomide has a manageable safety profile whether administered as a single agent or in...
5.
Luskin M, Heil D, Tan K, Choi S, Stadtmauer E, Schuster S, et al.
Am J Transplant
. 2015 May;
15(10):2665-73.
PMID: 25988622
We examined the associations of Epstein-Barr virus (EBV) status with characteristics and outcomes of posttransplantation lymphoproliferative disorder (PTLD) by studying 176 adult solid organ transplant recipients diagnosed with PTLD between...
6.
Ahmadi T, McQuade J, Porter D, Frey N, Loren A, Goldstein S, et al.
Bone Marrow Transplant
. 2011 Nov;
47(8):1082-6.
PMID: 22080969
We retrospectively analyzed 44 patients undergoing first-line treatment for mantle cell lymphoma with R-HyperCVAD, with or without rituximab (R) maintenance or auto-SCT. The primary study end point was PFS; secondary...
7.
Olin R, Vogl D, Porter D, Luger S, Schuster S, Tsai D, et al.
Bone Marrow Transplant
. 2008 Oct;
43(5):417-22.
PMID: 18850013
Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional chemotherapy or a second transplant, with no clear standard of...
8.
Tsai D, Douglas L, Andreadis C, Vogl D, Arnoldi S, Kotloff R, et al.
Am J Transplant
. 2008 Mar;
8(5):1016-24.
PMID: 18312608
While EBV PCR is used in the management of PTLD, the optimal primer set, relative importance of intracellular versus free plasma EBV, and the baseline profile in an organ transplant...
9.
Battineni M, Galetta S, Oh J, Lango M, Brooks J, Schuster S, et al.
AJNR Am J Neuroradiol
. 2007 May;
28(5):971-3.
PMID: 17494680
Idiopathic hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by prolonged eosinophilia without an identifiable cause, ultimately resulting in organ dysfunction. Three major types of neurologic involvement have been well...
10.
Svoboda J, Andreadis C, Elstrom R, Chong E, Downs L, Berkowitz A, et al.
Bone Marrow Transplant
. 2006 Jun;
38(3):211-6.
PMID: 16770314
We conducted a retrospective analysis of 50 lymphoma patients (Hodgkin's disease and non-Hodgkin's lymphoma) who had an 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) scan after at least two cycles of salvage...